EXACT Therapeutics AS (Euronext Growth: EXTX) will present data from its ACTIVATE Phase 1 trial at the bi-annual Contrast Media Research (CMR) Symposium 2024, held in Oslo, Norway, from October 6-9, 2024. The presentation, delivered by CEO Per Walday, will detail the first-in-human study of Acoustic Cluster Therapy (ACT) with chemotherapy in patients with liver metastases of colorectal origin.
The presentation, titled "First-in-Human Study of Acoustic Cluster Therapy with Chemotherapy and in Patients with Liver Metastases of Colorectal Cancer Origin," is scheduled for Tuesday, October 8th, at 9:45 a.m. (local time) during the Ultrasound Imaging 2 session. The company presentation will be available on the Investors section of EXACT Therapeutics' website.
Acoustic Cluster Therapy (ACT)
ACT is EXACT Therapeutics' proprietary technology platform designed for targeted therapeutic enhancement. It consists of microbubbles and microdroplets activated by ultrasound, which increases the targeted delivery of co-administered therapeutic agents. The company is focused on oncology, with potential applications across various therapeutic areas, including CNS disorders and immunotherapy.
Preclinical data supports ACT's therapeutic enhancement capabilities in multiple oncology models, including pancreatic, breast, colon, and prostate cancers, as well as its ability to penetrate the blood-brain barrier. The ACT platform is currently being evaluated in clinical trials, with positive interim data already released.
